home > ict > summer 2012 > adapting to change
International Clinical Trials

Adapting to Change

The 11th Annual Partnerships in Clinical Trials Congress and Exhibition focuses on the strategic and practical approaches to improving all partnerships between trial sponsors and their suppliers, in order to reduce costs, improve quality and accelerate clinical development.

The conference, on the 6th-9th November 2012, in the CCH Congress Center, Hamburg, Germany, covers the entire clinical development pipeline for pharmaceuticals and biotech, stretching from outsourced R&D and preclinical through to Phase 3. The key theme for this year’s event is ‘adapting to change: minimising risk through agile development.’ Through lively debate and in-depth discussions, the programme will examine managing risk strategically, with a defined set of criteria for risk-based monitoring. Other key themes include: tactics for efficient operational delivery; critical examination of strategic outsourcing models; and planning and measuring project success.

New additions to the 2012 programme include an expert opinion track, including a panel discussion that will look at the impact of CROs and other vendors going private. There will also be an initiative on outsourcing strategies for small- and medium-pharma and biotech, with a focussed networking opportunity for service providers to meet small- and mediumsized pharma companies.

The economic keynote presentation from Joe Nellis, Professor of International Management Economics, Director of Policy Strategy and Performance Community at Cranfield University will present “a competitive outlook for 2013 and beyond.” His take on leading change through strategic partnerships is simple: “what new businesses, what new alliances, what new partnerships have you not yet thought about which might be the right structures for the future?”

In the industry keynote presentation, John Orloff, Senior Vice President, Global Development and Chief Medical Officer, Novartis Pharma AG, will examine “high level strategic innovations for clinical trials: what needs to change?” This presentation will give an assessment of the current issues and challenges that the industry faces in clinical research.

For inspiration, Didi Hopkins, International Centre for Programme Management, Cranfield School of Management,

and Senior Trainer, The National Theatre, London, will present two workshops at the pre-conference symposium: “gravitas, power and presence – using the language of leadership to improve your public speaking”; and “women in leadership forum: be seen, be heard, be taken seriously.”

Delegates will also have the opportunity to hear from the true leader of the e-patient movement, Dave deBronkart, better known as ‘e-patient Dave’, and learn how this empowered patient beat stage 4 cancer.

The ‘leadership’ keynote comes from Itay Talgam, Music Director of the Tel-Aviv Symphony Orchestra and internationally renowned conductor. Through his humorous and interactive session, ‘lead like the great conductors: getting a brilliant performance without saying a word,’ Itay will examine how to resist micro-management and give space for your partners to perform.

One of the pre-conference workshops will deliver an audience with the FDA, assessing what is expected of risk-based monitoring. This will be presented by Ann Meeker-O’Connell, Acting Associate Director, Risk Science, Intelligence and Prioritization, US Food and Drug Administration, CDER.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.


To learn more about the event visit
To register:, quoting CQ3007EX15

Print this page
Send to a friend
Privacy statement
News and Press Releases

Significant improvement in overall survival with ERLEADA®▼ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer

BEERSE, BELGIUM, May 14, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the final analysis of the pivotal Phase 3 SPARTAN study demonstrating ERLEADA®▼ (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved overall survival (OS), compared to ADT alone, in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.1 Results will be presented at the American Society of Clinical Oncology (ASCO) Virtual Scientific Programme (Abstract #5516) beginning on Friday 29th May.
More info >>

White Papers

Delivering Fit For Purpose Biomanufacturing CHO Cell Lines

Fujifilm Diosynth Biotechnologies

The challenge during mammalian cell line development is to identify and isolate stable, high expressing cell lines producing product with the appropriate critical product quality attributes rapidly, reproducibly and with relative ease. Obtaining a host cell line that inherently exhibits desirable biomanufacturing attributes can therefore have a significantly positive effect on the identification of recombinant cell lines with desired traits during cell line development screens. In this study, we demonstrate that it is possible to exploit intrinsic heterogeneity within host cell populations and identify host cell lines which are more “fit for purpose”.
More info >>

Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement